What question did this study set out to answer?

The aim is to evaluate how ASXL1 mutations influence survival outcomes in acute myeloid leukemia (AML) patients treated with lower intensity therapy.

May 8, 2026Open Access

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Key Points

The aim is to evaluate how ASXL1 mutations influence survival outcomes in acute myeloid leukemia (AML) patients treated with lower intensity therapy.
Retrospective analysis of 554 adults with newly diagnosed acute myeloid leukemia treated with lower intensity therapy.
Subjects were stratified based on ASXL1 mutation status and treatment backbone.
ASXL1 mutations were independently associated with inferior overall survival in patients.
The classification of AML as intermediate risk may be affected by the specific lower intensity therapy used.

Abstract

BACKGROUND: across different contemporary LIT+VEN backbones remains controversial. METHODS: A retrospective analysis in 554 adults with newly diagnosed AML treated with LIT was conducted, stratified by ASXL1 mutation status and treatment backbone. RESULTS: remained independently associated with inferior overall survival. CONCLUSIONS: AML may be more appropriately classified as intermediate risk in the context of LIT+VEN-based therapy, with the depth of impact influenced by the specific LIT backbone.

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Key Points

Abstract

Cite This Study